Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug 1;500(1):72-6.
doi: 10.1016/j.neulet.2011.06.004. Epub 2011 Jun 13.

The Abnormal Cannabidiol Analogue O-1602 Reduces Nociception in a Rat Model of Acute Arthritis via the Putative Cannabinoid Receptor GPR55

Affiliations

The Abnormal Cannabidiol Analogue O-1602 Reduces Nociception in a Rat Model of Acute Arthritis via the Putative Cannabinoid Receptor GPR55

Niklas Schuelert et al. Neurosci Lett. .

Abstract

Cannabinoids classically act via CB₁ and CB₂ receptors to modulate nociception; however, recent findings suggest that some cannabinoids bind to atypical receptors. One such receptor is GPR55 which is activated by the abnormal cannabidiol analogue O-1602. This study investigated whether the synthetic GPR55 agonist O-1602 can alter joint nociception in a rat model of acute joint inflammation. Acute (24 h) inflammatory joint pain was induced in male Wistar rats by intra-articular injection of 2% kaolin and 2% carrageenan. Single unit extracellular recordings were made from arthritic joint afferents in response to mechanical rotation of the knee. Peripheral administration of O-1602 significantly reduced movement-evoked firing of nociceptive C fibres and this effect was blocked by the GPR55 receptor antagonist O-1918. Co-administration of the CB₁ and CB₂ antagonists (AM281 and AM630 respectively) had no effect on O-1602 responses. This study clearly shows that atypical cannabinoid receptors are involved in joint nociception and these novel targets may be advantageous for the treatment of inflammatory pain.

Similar articles

See all similar articles

Cited by 13 articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

Feedback